Alembic Q4 FY26: Growth Holds Up as R and D Rises and Mix Shifts

Alembic Pharmaceuticals closed Q4 FY26 with steady top line growth and a clear push on research spend. Revenue for the quarter came in at INR 18.48 billion, up 4 percent year on year. EBITDA before R and D was INR 4.55 billion and the pre R and D margin improved to 25 percent. Reported profit attributable to shareholders was INR 2.03 billion, up 29 percent year on year, with a net profit margin of 11 percent.

The quarter had two stories running in parallel. The first was demand and execution across businesses, led by the US formulations franchise and a stable India branded business. The second was investment intensity. R and D rose to 11 percent of revenue in Q4 and was up 39 percent year on year. Management described the increase as driven by one off development and higher filings versus the prior year. That mix matters because it supports the longer cycle of product approvals and launches, but it can also reshape near term profit optics depending on cadence.

How each business contributed

India Branded Business delivered INR 5.68 billion in Q4 revenue, up 4 percent year on year. The segment remains a large contributor to consolidated revenue, representing 33 percent of FY26 revenue. The business also continues to scale on a multi year basis, with FY26 revenue of INR 24.58 billion versus INR 19.26 billion in FY22, a 6 percent CAGR across FY22 to FY26. Operationally, Alembic highlighted scale in the field with more than 5,500 medical representatives across 21 marketing divisions, a prescriber base of 2,46,000, and 208 brands. The company is ranked 21st in the Indian Pharmaceutical Market and holds a 1.2 percent market share as per IQVIA MAT Mar 2026.

Within India, Animal Health stood out for growth. It grew 27 percent year on year in Q4 to INR 1,241 million. The FY22 to FY26 revenue trend indicates a 22 percent CAGR, reaching INR 5,191 million in FY26. The sales mix in Q4 was led by antibiotics at 38 percent and feed supplements at 27 percent, with tonics, supportive therapy, and antiparasitics making up the rest.

The US business was the key growth driver in formulations for the quarter. Revenue rose 11 percent year on year to INR 5.64 billion in Q4, and FY26 revenue grew 13 percent year on year to INR 22.06 billion. Alembic ended the year with 235 approved ANDAs including 19 tentative approvals, on cumulative filings of 274. In Q4 FY26, the company filed 5 ANDAs and received 4 approvals. It also launched 15 products in FY26, taking total products commercialized to 178. The company also noted that a US branded business was launched in Q4, with the first branded product Pivya launched in 2026.

Ex US formulations were the soft spot in Q4 with revenue down 2 percent year on year to INR 3.69 billion, though the annual picture remained strong. FY26 revenue for Ex US rose 20 percent year on year to INR 14.94 billion, reflecting an 18 percent CAGR from FY22 to FY26. The company attributed the quarterly softness to a higher base effect and one off variances, and pointed to growth support from launches and geographic diversification. Subsidiaries have been set up in Thailand, Philippines, and Germany, and partnerships remain active across Europe, Canada, Australia, Brazil, Chile, and South Africa.

API revenue was steady in the quarter at INR 3.47 billion, up 2 percent year on year, while FY26 revenue grew 5 percent year on year to INR 11.87 billion. The company said volume was strong but pricing remained a challenge. In Q4 FY26, Alembic filed 6 US DMFs and has 149 cumulative DMF filings with the US FDA. Cost efficiency remains a stated focus in this segment.

Profitability: what improved and what got absorbed

At the headline level, Q4 profit rose sharply year on year, but the path through the P and L is uneven. Revenue grew 4 percent and total expenses grew 9 percent year on year, reflecting higher employee costs, depreciation, and other expenses. Profit before tax came in at INR 1.19 billion, down 38 percent year on year, while profit attributable to shareholders rose to INR 2.03 billion due to a tax credit of minus INR 0.83 billion in Q4 FY26.

A useful lens here is the company’s presentation of profitability before R and D. Pre R and D EBITDA margin improved from 24 percent to 25 percent, and pre R and D EBITDA grew 8 percent year on year to INR 4.55 billion. That suggests underlying operating efficiency held up, while the deliberate choice to spend more on development and filings pressed on reported operating metrics.

On a full year basis, revenue from operations increased 10 percent to INR 73.45 billion and profit attributable to shareholders increased 16 percent to INR 6.75 billion. EBITDA for the year was INR 11.77 billion and the EBITDA margin held at 16 percent. Finance costs increased 19 percent year on year in FY26 to INR 0.94 billion, while depreciation and amortization increased 14 percent to INR 3.19 billion, reflecting the asset base and commissioning cadence.

R and D cadence and the US pipeline angle

Alembic’s Q4 message on R and D was direct: spend rose because of one off development and higher filings. In Q4, R and D spend increased from INR 1.51 billion to INR 2.09 billion. For FY26, R and D spend was INR 7.1 billion, up from INR 5.2 billion in FY25, and R and D as a share of sales moved up to 9.6 percent.

The filings and approvals chart shows a lower number of filings in recent years compared with FY22 and FY23, but approvals remain meaningful. FY26 showed 10 filings and 15 approvals, while FY25 showed 8 filings and 23 approvals. For investors, that split matters because approvals and launches convert prior years’ filings into revenue, while fresh filings seed the next cycle. The US business also appears to be broadening its platform mix. Approved ANDAs span oral solids, derma, ophthalmic, and injectables. The company also highlighted a strategic evolution toward complex platforms and specialty segments, alongside the launch of a US branded business.

Manufacturing readiness and compliance discipline also remain central to monetizing that pipeline. Alembic listed 10 manufacturing facilities and presented recent audit timelines. Notably, the F3 Karkhadi facility for general injectables and ophthalmic had a USFDA audit in Feb 2026, with response to observations submitted and an Establishment Inspection Report awaited. The India formulation Indore site received WHO certification in Apr 2026 following a Mar 2026 audit. These checkpoints do not change quarterly revenue by themselves, but they can influence launch flexibility and supply confidence.

Balance of priorities: scale, investment, and sustainability

The FY26 revenue mix shows a business that is not dependent on a single geography. India branded and US formulations are nearly equal in annual mix, with Ex US and API providing additional balance. That diversification can reduce volatility, but it also creates multiple execution fronts. The quarter showed that clearly: US grew strongly, India held steady, API stayed stable, and Ex US had a soft quarter while still growing strongly on an annual basis.

Capital allocation signals are also visible. FY26 capex was INR 4.32 billion, lower than FY25’s INR 5.75 billion, while ROCE excluding assets not deployed and exceptional items was 15 percent in FY26 versus 16 percent in FY25. In plain terms, the company is investing heavily in development while maintaining a measured capex envelope, and it is trying to preserve return metrics through mix and efficiency.

Alembic also tied long term sustainability goals to operational planning. The company’s targets include net zero by 2050 with SBTi approved emission reduction targets, water neutrality by 2027, and planting 50,000 trees by 2027. It highlighted a committed 24 MW solar park at Bhatpur in Vadodara, 81 percent treated water recycling, and specific water consumption reduction of 20 percent. ESG disclosures do not change near term earnings, but they can lower operating risk over time, especially for an export focused manufacturer exposed to tightening customer and regulator expectations.

Takeaways for investors

Q4 FY26 was a quarter of steady growth with visible reinvestment. Revenue growth was modest at 4 percent, but segment execution in the US remained strong and India stayed resilient. The sharp rise in reported PAT came alongside a weak profit before tax line in Q4, so investors should read the quarter through both lenses: operating delivery held up before R and D, while the reported bottom line benefited from a tax credit.

The bigger picture is that Alembic is leaning into its pipeline. R and D stepped up in Q4 and for FY26, and the company continues to convert approvals into launches in the US while broadening into complex platforms and starting a US branded effort. If Ex US performance normalizes after the base effect and one off variances, and if regulatory and manufacturing execution stays on track, FY26’s mix and pipeline build can support a more durable growth profile.